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Abstract. Dengue, endemic in Puerto Rico, reached a record high in 2010. To inform policy makers, we derived
annual economic cost. We assessed direct and indirect costs of hospitalized and ambulatory dengue illness in 2010 dollars
through surveillance data and interviews with 100 laboratory-confirmed dengue patients treated in 2008–2010. We
corrected for underreporting by using setting-specific expansion factors. Work absenteeism because of a dengue
episode exceeded the absenteeism for an episode of influenza or acute otitis media. From 2002 to 2010, the aggregate
annual cost of dengue illness averaged $38.7 million, of which 70% was for adults (age 15+ years). Hospitalized
patients accounted for 63% of the cost of dengue illness, and fatal cases represented an additional 17%. Households
funded 48% of dengue illness cost, the government funded 24%, insurance funded 22%, and employers funded 7%.
Including dengue surveillance and vector control activities, the overall annual cost of dengue was $46.45 million
($12.47 per capita).
INTRODUCTION
Dengue fever, or break bone fever, is an infectious tropical
disease transmitted to humans through bites of infected Aedes
mosquitos, principally Ae. aegypti.
1 Dengue has been increas-
ingly recognized as a major global public health concern since
the 1950s.
2,3 It is endemic in more than 100 countries and is
expanding to new regions, including Africa and West Asia,
4–6
with nearly 3 billion people at risk of infection.
7 The World
Health Organization (WHO) reported a 30-fold increase in
dengue incidence over the past 50 years.
6 After adjusting for
underreporting, an estimated 100 to 200 million dengue infec-
tions, 34 million cases of dengue fever, 2 million cases of den-
gue hemorrhagic fever, and 20,000 dengue deaths occur
yearly,
8–10 making dengue the most important vector-borne
viral disease of humans.
8
The emergence of dengue has resulted in considerable
threats to population health and caused substantial costs.
11–13
A dynamic disease with a wide clinical spectrum that ranges
fromanasymptomaticinfectiontoaself-limitingfebrileillnessto
severe dengue and to a life-threatening condition characterized
by extensive capillary permeability and shock,
5,6 dengue is consid-
eredtheworld’smostrapidlyspreadingmosquitoborneillness.
14,15
Dengue is a flavivirus virus with four different antigenically
distinct serotypes (DENV1–DENV4).
16,17 Infection with one
dengue virus serotype provides lifelong immunity to reinfection
by the homologous serotype.
18 However, cross-protection het-
erotypic immunity typically lasts from 2 weeks to 3 months,
19
but thereafter, individuals infected with one serotype are fully
susceptible to infection with other types; these subsequent
infections may be accompanied by increased severity of the
disease.
16,18 One factor leading to severe dengue is “antibody-
mediated immune enhancement, where antibodies developed
fromapreviousinfectioncauseenhancedviraluptakewithanew
infection of a different serotype.”
20,21 Other factors relate to the
person’s genetic risk, the strain and serotype of the infecting
virus, the degree of viremia, and immune pathology.
5,9,22,23
Currently, there is no specific medication or antibiotic to
treat dengue.
1,5,14 For non-severe minor febrile cases, treat-
ment includes relief of symptoms, rest, and adequate hydra-
tion. Because the disease may progress rapidly, careful
management is needed, sometimes requiring hospitalization.
Dengue hemorrhagic fever requires continued monitoring of
vital signs and urine output, whereas dengue shock syndrome
is considered a medical emergency that requires intensive
care unit hospitalization.
4,6
Puerto Rico, an unincorporated territory of the United
States, is one of the few areas within the United States with
substantial dengue transmission.
24 According to the Dengue
Branch of the Centers for Disease Control and Prevention
(CDC) in Puerto Rico, 61,844 suspected dengue cases were
reported between 2002 and 2010.
25 Of these cases, 22,648 cases
were confirmed dengue cases, with nearly 1.6% (N = 350)
having dengue hemorrhagic fever (DHF). In 2010, Puerto Rico
declared an epidemic of dengue with its largest ever outbreak
of over 21,000 suspected dengue cases, of which 46% were
laboratory confirmed with a general infection rate of 24.94 per
10,000.
25 Because mild cases are often not reported, the inci-
dence in 2010 was probably several times higher.
26
Currently, the only available control strategies are reducing
mosquito abundance, reducing adult mosquito lifespan, and
preventing mosquito–human contact.
13,14 The CDC Dengue
Branch, the Puerto Rico Department of Health, and larger
municipalities maintain surveillance systems to monitor the epi-
demic of dengue, inform policy makers, and recommend con-
trol measures.
27 Puerto Rico law requires reporting all cases of
dengue fever and DHF in both ambulatory and hospitalized
settings.
25,28 Physicians are given special training to improve
the diagnosis and treatment of dengue.
28 Through mass media
and educational campaigns, citizens are educated on prevention
of dengue and control of vectors.
27,29 Larger municipalities and
the Puerto Rico Department of Health conduct vector pro-
grams using recommended guidelines.
13,30
Costs for dengue treatment are incurred not only by the
government but also by insurers, employers, patients, and
their families. The 1977 dengue epidemic in Puerto Rico cost
$6.16 million for medical treatment and prevention,
31 and the
1994 epidemic cost $12 million for medical treatment alone.
32
However, as numbers of suspected dengue cases have been
escalating, with evidence of increasing disease severity
30 and
substantial variation among years (from a low of 3,162 in 2002
to a high of 21,319 in 2010),
25 more research summarizing the
numbers of cases and costs of treatment over a series of years
is needed for a more comprehensive picture.
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745To address the variability of dengue cases and cost across
years, this paper estimates the annual average aggregate eco-
nomic costs of treated dengue cases in Puerto Rico during the
period of 2002 through 2010. We use data collected from multi-
ple sources, including patients, insurers, and clinicians, combined
with the results of our previous study on costs of dengue surveil-
lance and vector control,
27 and incorporate sensitivity analyses.
METHODS
Sample selection. Working from the compulsorily reported
dengue cases
33 during the prospective study period of July of
2008 through March of 2010, the CDC Dengue Branch pro-
vided the study interviewers with a password-protected list
of laboratory-confirmed dengue patients who met the WHO
clinical case definition of dengue.
34 For each case, CDC staff
and the study interviewers contacted the facility where the
patient sought care to request patient’s contact information.
Public health officials then contacted the patient to update his/
her contact information and obtain their consent for future
interviews when they were fully recovered from the dengue
episode. Appendix 1 describes the study’s sampling and enroll-
ment processes. The final sample consisted of 100 laboratory-
confirmed dengue patients who had an episode of dengue
during the period of 2008–2010, consisting of 44 children
(i.e., patients < 15 years; 31 hospitalized and 13 received
ambulatory care) and 56 adults (i.e., patients aged 15+ years;
36 hospitalized and 20 received ambulatory care).
Cost of non-fatal ambulatory and hospitalized cases. The
Institutional Review Boards (IRBs) at Brandeis University
and the CDC reviewed and approved the research protocol.
After receiving patients’ or legal surrogates’ consents for the
interview and access to medical and insurance records, the
study interviewer contacted each patient (or parent) at the time
of the patient’s full recovery from the illness episode. The
interviewers followed a structured questionnaire adapted
from a previous study,
12 which was previously validated on
a prospective sample of dengue hospitalized and ambula-
tory patients, that was programmed into a handheld device
(personal data assistant) with QDS software and translated
into Spanish. The software’s automated branching and cross-
referencing validated responses and obviated most coding and
data entry. The survey instrument measured patients’ quali-
ties of life during a dengue episode, duration of illness, use of
medical services, dengue impact on schooling, work produc-
tivity, and leisure time, out of pocket illness-related payments,
and income lost as well as the time and income loss of care-
takers because of the patient’s illness. Standard routines for
cleaning, consistency checks, and analysis were performed.
Cost analysis framework. The direct medical cost captures
the payments by insurers, government, employers, and house-
holds (including copayment and deductibles, if any) for med-
ical services and prescriptions. For hospitalized cases, payments
by insurers were compiled from insurance companies and/or
hospital financial departments. For ambulatory cases, out-of-
pocket payments, number of visits, and types of settings were
obtained from patients during the interview, whereas insurance
payments were obtained from insurers. Payments were
imputed for 7 of 100 patients where actual amounts were not
available through any source. The imputation was based on
other patients in the study with similar age, days of sickness,
severity, number of ambulatory visits, type of provider, and
number of hospitalized days (including the number of days
spent at the intensive care unit [ICU]). Some hospitalized
patients received ambulatory care in addition to inpatient
care, which was often not reflected in hospital bills or insur-
ance claims. For the cost of ambulatory treatment, we used
insurance and facility-level data as well as patients’ estimates
of the cost of the ambulatory medical services received and
associated charges (e.g., prescription charges and other out
of pocket payments) through the interviews. We estimated
the actual payments for ambulatory services as 70% of their
median charges based on the ratio under the government
health insurance plan, which covers most of the island’s pop-
ulation.
35 For 61 hospitalized subjects, we were able to vali-
date self-reported data on days of hospitalization using
administrative data from hospitals and insurers. We calcu-
lated the ratio of the self-reported number to the number
shown in insurance and hospital records and computed the
mean and 95% confidence interval.
Direct non-medical cost represents expenses for transpor-
tation, meals, and lodging while seeking care during the den-
gue episode; this information was obtained during patient
interviews. Indirect cost consists of the opportunity cost asso-
ciated with days of schooling lost for children and working
days lost for both patients and caregivers because of illness.
Although it was not possible to access school and work
records to confirm absenteeism from work or school, our
validation of self-reported length of stay indicated that
respondents generally reported their illness accurately. For
school children, the duration of illness and the number of days
absent from school were obtained from the interviews. The
cost of $42.75 per day of schooling (derived by dividing the
annual budget of the Puerto Rico Department of Education
by Puerto Rico school enrollment according to the US Census
Bureau
36) was used to calculate the economic cost of school-
ing lost because of the illness episode. For adults, the duration
of illness and the number of days absent from work, if any, were
obtained through the interview. The minimum daily wage of
$49.20
37 was used to estimate the opportunity cost of absence
from work. Similarly, we asked whether patients had any care-
givers during their illness. If the caregivers were paid, we
obtained the amount paid directly from the interview. If care-
givers were not paid for their services (e.g., family members),
we asked patients to estimate the days of care provided by
caregivers, and we estimated the costs of care using the afore-
mentioned minimum daily wage.
Projection of annual number of dengue cases. The number
of laboratory-positive confirmed dengue cases between
2002 and 2010 was obtained from the CDC’s Dengue Branch
in Puerto Rico and the Puerto Rico Department of Health.
To adjust for underreporting, we used an expansion factor of
2.42 for hospitalized and fatal cases and 10 for ambulatory
cases.
38 The work by Meltzer and others
39 estimated expan-
sion factors of 10–27 to project the number of dengue cases
based on reported cases through 1994.
39,40 We chose the
lower bound for ambulatory cases, because dengue awareness
has increased; additionally, Puerto Rico’s dengue surveillance
system has strengthened appreciably from 1994 to 2010.
28,29,41
Our expansion factor for fatal cases is consistent with a recent
study showing that enhanced surveillance of deaths from
acute fever episodes revealed a substantial number of dengue
deaths not previously recognized.
42
746 HALASA AND OTHERSCost of fatal dengue cases. We assumed that the fatal
cases will be severe cases treated at hospitals and will have the
same age distribution as hospitalized cases. We estimated the
cost of fatal dengue as the economic value of the years lost
from premature death caused by dengue. We estimated the
average age of children who died prematurely because of
dengue to be 8 years and the average age for adults who died
prematurely because of dengue to be 32 years. We calculated
their years of life lost as the sum of their discounted (at an
annual rate of 3%) remaining life expectancy at their age of
death based on the US Social Security Administration’s period
life table.
43 Then, we multiplied the average discounted years
by Puerto Rico’s gross domestic product (GDP) per capita for
2010.
40 Because most fatal cases die within 4 or 5 days of
illness,
42 we estimated the aggregate cost of fatal cases as the
cost of premature death because of dengue in addition to the
direct medical and non-medical costs and indirect cost of an
average cost of a hospitalized case. Reported dengue deaths
represented 0.36% of hospitalized cases (annual average of
16 deaths per 4,431 cases).
Projection of annual cost of dengue. The total cost for
each of the six categories of cases (child hospitalized [ambu-
latory and death] and adult hospitalized [ambulatory and
death]) was estimated by multiplying the average cost per
case by the projected number of these cases. The overall cost
was computed using the weighted average cost of child and
adult patients using projected numbers of cases. The cost was
further broken down by financing agent categories (insurer,
household, government, and employer), type of cost (direct
medical cost, direct non-medical cost, and indirect cost), and
type of care (hospitalization and ambulatory care). All costs
were standardized to 2010 US dollars.
Uncertainty of total cost estimation and sensitivity analysis.
After we calculated the treatment cost for each case,
we bootstrapped all types of treatment costs, including the
aggregate cost, with 10,000 repetitions and generated a 95%
confidence interval (CI) of the dengue illness cost. The
bootstrapping was conducted using MATLAB 2009b
(MathWorks, Inc., Natick, MA) for hospitalized and ambula-
tory cases only. We used various expansion factors to estimate
the number of dengue cases in Puerto Rico.
31,39,44 These fac-
tors vary inversely with the severity of the epidemic under
study and the quality of the surveillance and reporting sys-
tems. Our sensitivity analyses examined a range of expansion
factors for ambulatory care ranging from 5 to 27 based on our
literature review.
39
RESULTS
Table 1 shows the reported and projected average number
of ambulatory and hospitalized dengue cases as well as the
average number of fatal dengue cases (included in the hospi-
talized cases) for the years 2002 through 2010.
On average, hospitalized patients averaged 4.5 days in hos-
pital (3.9 days in a ward and 0.6 day in ICU). Our validation
of self-reported length of stay found that self-reported hospi-
talized nights agreed reasonably well with the number shown
in administrative data. The average ratio was 1.16, with a 95%
CI of 1.05 to 1.26. Table 2 shows the average cost per dengue
case by age group and types of cost and care as well as the
average days affected from a dengue episode by age group.
The average costs per hospitalized case and per ambulatory
case were similar between children and adults. Children
tended to have higher direct medical costs than adults, but
the difference was not statistically significant. In contrast,
hospitalized adults had much higher indirect costs (P < 0.05),
which compensated for their lower direct costs. The direct
nonmedical cost was higher for children in both hospitalized
(P < 0.01) and ambulatory (P < 0.05) settings. In ambulatory
care, indirect costs were the major component of a dengue
episode cost, constituting 62% and 71% of the total cost in
child and adult dengue cases, respectively. We also found that
the cost of the dengue treatment varied greatly among
patients. The coefficients of variation for child and adult hos-
pitalized cases were 57% and 51%, respectively, and for child
and adult ambulatory cases were 45% and 56%, respectively.
The average cost per death was $428,559 overall, being
$474,712 for a child death and $407,903 for an adult death.
In general, the average days of a patient’s school and work
absenteeism were 7.2 days, of which 5.3 days were days of
work absenteeism. Time lost because of caregiving raised
the number of affected days because of a dengue episode to
30.5 days. We found no statistically significant differences
between children and adults.
Table 3 shows the cost per case by age group and source of
financing. In absolute costs, households incurred a higher
Table 1
Average annual number of reported laboratory-positive dengue and
projected dengue cases and the average fatal cases between 2002
and 2010
Age group Hospitalized Ambulatory Total Fatal* Row (%)
Reported cases
Children < 15 years 566 146 712 2 29
Adults 15+ years 1,265 445 1,710 5 71
Total 1,831 591 2,422 7 100
Projected cases
Children < 15 years 1,370 1,460 2,830 5 27
Adults 15+ years 3,061 4,450 7,511 11 73
Total 4,431 5,910 10,341 16 100
*Fatal cases are included in the number of hospitalized cases.
The projection of hospitalized and fatal cases uses an expansion factor of 2.42 from a
laboratory-based capture/recapture surveillance system for Puerto Rico (average of 1991–1995).
Ambulatory cases use the lower bound of 10 from the range in the work by Meltzer et al.
39
Table 2
Average cost per adult and child case by setting and type of cost and
days affected by a dengue episode from 2002 to 2010
Setting and type of cost Children Adults All
t
Statistic
Hospitalized (total) $5,387 $5,518 $5,497 −0.18
Direct medical cost $4,031 $3,515 $3,687 0.90
Direct non-medical
cost
$187 $123 $144 2.69*
Indirect costs $1,170 $1,880 $1,666 −2.29†
Ambulatory (total) $1,236 $1,293 $1,279 −0.24
Direct medical cost $425 $358 $375 1.00
Direct non-medical
cost
$39 $19 $24 2.47*
Indirect costs $773 $916 $880 −0.58
Fatal (indirect cost)‡ $474,712 $407,903 $432,188 na
All settings $4,075 $3,604 $3,733 na
Days affected (patient and caregivers)
School- and work-
related absenteeism
6.5 8.3 7.2 −0.99
Work absenteeism 4.3 6.9 5.3 −1.64
Total affected 30.9 29.9 30.5 0.31
*P < 0.01.
†P < 0.05.
‡ The fatal indirect cost indicates the cost of premature death from dengue.
na = not applicable.
DENGUE COSTS IN PUERTO RICO 747financial burden for an adult hospitalized dengue patient
compared with a hospitalized child dengue case (P < 0.05).
The pattern for ambulatory cases was similar but not statisti-
cally significant. Households paid 21% of the total cost for
child hospitalized dengue cases and 37% for adult hospital-
ized cases. In the ambulatory setting, households accounted
for 51% of total cost for a child with dengue and 63% for an
adult with dengue. The government paid about 30% and 29%
of hospitalized dengue cases costs for child and adult cases,
respectively. For ambulatory cases, the government paid a
larger amount for the treatment of child dengue cases (29%
compared with 16% for adult cases). Among fatal dengue
cases, households bore 89.8% of the total indirect cost,
whereas the government incurred 10.2% of the total indirect
cost as lost tax revenues.
45
Table 4 shows the aggregate cost of treated dengue cases
based on the projected number of dengue cases from Table 1.
Our analysis estimated an annual aggregate dengue illness cost
of $38.7 million in Puerto Rico, equivalent to $10.40 per capita
per year. Of all the illness cost, children represented 30%,
whereas adults constituted the remaining 70% (not shown in
the table); 63% of illness cost was incurred by hospitalized
patients, 20% of illness cost was incurred by ambulatory cases,
and 18% of illness cost was incurred by the indirect cost of fatal
cases. Figure 1 illustrates the distribution of estimated total
treatment cost of dengue. The CI shows that the total treatment
cost of dengue was estimated between $28.1 and $36.5 million,
which is equivalent to $7.54–9.80 per capita in 2010.
We also disaggregated dengue illness costs by type of cost
and source of financing. For the aggregate cost, the cost of
fatal cases was computed as the sum of the direct medical and
non-medical costs and the indirect cost of an average cost of
hospitalized cases plus the indirect cost of dengue premature
death. We found that direct non-medical cost represented
only a minuscule 2% share of total costs. Direct medical cost
represented 48% of aggregate treatment cost, and indirect
costs represented 50%. Examining the aggregate cost by
sources of financing, we found that households fund the
highest share (48%) followed by government (24%), insurers
(22%), and employers (7%). Households in Puerto Rico bear
most of the financial burden from dengue illness. Table 5
shows the total cost by sources of financing and type of costs
to understand the contribution of households to each type of
Table 4
Aggregate annual cost of projected dengue case by setting, type of cost, source of financing, and result of the bootstrapping with 95% CI of the
dengue illness cost from 2002 to 2010 (in thousands of 2010 US dollars)
Type or source Hospitalized Ambulatory Fatal Total SE*
95% CI
Col. (%) Lower* Upper*
Breakdown by type of cost
Direct medical costs $16,280 $2,215 $1 $18,495 $1,591 $16 $21,976 48
Direct non-medical costs $634 $141 $0 $775 $62 $1 $916 2
Indirect costs $7,356 $5,203 $6,914 $19,474 $1,248 $11 $15,509 50
Total $24,270 $7,559 $6,915 $38,744 $2,148 $28,101 $36,508 100
Breakdown by source of financing
Insurance $7,775 $616 $0 $8,392 $1,354 $6,033 $11,437 22
Households $7,789 $4,516 $6,209 $18,514 $1,337 $10,008 $15,365 48
Employers $1,575 $1,015 $0 $2,590 $413 $1,914 $3,597 7
Government $7,131 $1,413 $705 $9,248 $1,440 $6,203 $12,026 24
Total $24,270 $7,559 $6,915 $38,744 $2,148 $28,101 $36,508 100
Row (%) 63 20 18 100
*These values were obtained through the bootstrapping analysis for ambulatory and hospitalized cases only. They do not include the indirect cost of fatal cases because of premature death.
The cost of fatal cases is the sum of direct medical and non-medical costs and indirect cost of an average cost of a hospitalized case plus the indirect cost of dengue premature death.
Figure 1. Frequency distribution of estimated annual aggregate
dengue treatment cost in Puerto Rico in $US million (2002–2010).
Table 3
Average cost per child and adult case by setting and financing source
from 2002 to 2010
Setting and financing source Child Adult All
t
Statistic
Hospitalized (non-fatal) $5,387 $5,518 $5,497 −0.18
Insurance $2,353 $1,487 $1,761 1.45
Households $1,156 $2,027 $1,764 −2.29*
Employers $285 $387 $357 −0.97
Government $1,593 $1,616 $1,615 −0.04
Ambulatory $1,236 $1,293 $1,279 −0.24
Insurance $102 $105 $104 −0.04
Households $627 $809 $764 −0.82
Employers $154 $178 $172 −0.26
Government $353 $202 $239 1.89
Fatal
† $474,712 $407,903 $432,188 –
Insurance –– $0 –
Households $426,291 $366,297 $388,063 –
Employers –– $0 –
Government $48,421 $41,606 $44,063 –
*P < 0.05.
†The cost of fatal cases represents the indirect cost of premature death from dengue. This
cost represents the discounted cost of the Puerto Rican GDP per capita and is shared by both
households (89.8%) and the government (10.2%).
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were because of hidden indirect costs, such as the cost of
absenteeism from work and school and the premature death
of a household member from dengue.
Table 6 presents the total cost of treated dengue cases
corresponding to the range of expansion factors on ambulatory
care. With the increase of the expansion factors from 5 to 27, the
total treatment cost of dengue increased by 43% from $26.2
($7.03 per capita) to $37.49 million ($1.06 per capita). With
larger expansion factors, more financial burden shifted to house-
holds, because households have to pay higher relative costs for
ambulatory care than for inpatient care. The contribution of
households to the total treatment cost of dengue increases to
51.6% if we use an expansion factor of 27 for ambulatory care
compared with 48.7% if we use an expansion factor of 5.
The aggregate average annual economic cost of dengue
illness in Puerto Rico is $38.7 million ($10.40 per capita). As
shown in Table 7, combining the cost of dengue illness with
costs associated with dengue surveillance and vector control
activities, estimated recently for the years 2002 to 2007 in
Puerto Rico and adjusted to 2010 price levels,
27 increases the
total economic cost of dengue illness to $46.4 million ($12.47
per capita). Analyzing the overall economic cost of dengue in
Puerto Rico, including dengue surveillance and vector control
activities, indicates that 36% of this cost is incurred by the
government (both the state and municipalities), 40% is
incurred by households, 18% is incurred by insurance, and
6% is incurred by employers.
DISCUSSION
The burden of dengue illness is high in Puerto Rico: the
weighted average cost of treatment per case is $3,078,
representing 19% of the per capita GDP ($16,300 in 2010).
40
Of this burden, 48% is incurred by households, 24% is
incurred by the government, 22% is incurred by insurance,
and 7% is incurred by employers; 50% of this cost is because
of productivity losses (indirect cost) that affect households
and employers as well as the government. The number of
days affected by dengue for both patients and house-
hold members averaged 30.5 days per case, of which 24.6%
(7.2 days) are because of absenteeism from school and work.
The aggregate time lost for all patients and household mem-
bers was 136 person-years for laboratory-confirmed cases and
579 person-years lost after adjustment for underreporting.
The economic impact of dengue per case on work absentee-
ism in Puerto Rico (5.3 days) is higher than the corresponding
numbers of workdays missed for the following other condi-
tions: laboratory-confirmed influenza in the United States
(2.8–4.9 days),
46 laboratory-confirmed influenza in other
industrialized countries (1.5–4.9 days),
47 1.6 days for work-
ing mothers and 0.6 days for working fathers of children with
acute otitis media (AOM) in Israel, and 1.9 days for AOM
in Finland.
48,49
During the last decade, several studies have addressed the
economic burden of dengue in various settings.
12,50–61 Some of
these studies were retrospective and relied on official records,
some focused on hospitalized cases (treatment setting), and
others reported cases and direct medical cost. Few conducted
a comprehensive analysis of the economic impact of dengue
using a prospective design and included direct non-medical
cost as well as indirect costs to the overall cost of den-
gue.
12,52,58,61 Moreover, these studies were facility-based
and focused on limited geographic areas, population, or an
epidemic year.
Table 6
Sensitivity analysis on the aggregate average annual cost of dengue illness using a range of expansion factors for ambulatory care (in millions of
US dollars) from 2002 to 2010
Type of cost and source of financing
Possible expansion factor
5 7 9 11 13 15 17 19 21 23 25 27
Breakdown by type of cost ($)
Direct medical costs 12.24 12.55 12.86 13.17 13.49 13.80 14.11 14.42 14.73 15.04 15.36 15.67
Direct non-medical costs 0.50 0.52 0.55 0.57 0.59 0.61 0.63 0.65 0.67 0.69 0.71 0.73
Indirect costs 13.44 14.13 14.83 15.52 16.22 16.92 17.61 18.31 19.01 19.70 20.40 21.09
Breakdown by source of financing ($)
Insurance 5.89 5.97 6.06 6.14 6.23 6.31 6.40 6.48 6.57 6.65 6.74 6.82
Households 12.75 13.35 13.96 14.56 15.16 15.76 16.36 16.96 17.56 18.16 18.76 19.36
Employers 1.38 1.52 1.65 1.79 1.93 2.06 2.20 2.33 2.47 2.61 2.74 2.88
Government 6.16 6.36 6.57 6.78 6.98 7.19 7.40 7.60 7.81 8.02 8.22 8.43
Total 26.18 27.21 28.24 29.26 30.29 31.32 32.35 33.38 34.41 35.44 36.47 37.49
Table 7
The average annual aggregate economic cost of dengue in Puerto
Rico for 2002–2010
Aggregate amount
(million)
Per capita
amount Percent
Illness costs
Total illness cost $38.74 $10.40 83.4
Direct cost $19.27 $5.17 41.5
Indirect cost $19.47 $5.23 41.9
Vector control and surveillance*
Total prevention cost† $7.70 $2.07 16.6
Vector control $6.98 $1.87 15.0
Surveillance $0.73 $0.20 1.6
Total $46.45 $12.47 100.0
*Excludes the in-kind contribution of CDC dengue branch in Puerto Rico.
†Prevention cost refers to dengue vector control and surveillance.
Table 5
Aggregate average annual financing of projected dengue cases by
type of cost and source of financing averaged per year (2002–2010;
in thousands of 2010 US dollars)
Source of
financing
Direct medical
costs
Direct non-
medical costs
Indirect
costs
All types of
costs Percent
Insurance $8,391 $0 $0 $8,391 22
Households $2,305 $775 $15,434 $18,514 48
Employers $0 $0 $2,590 $2,590 7
Government $7,798 $0 $1,450 $9,248 24
Total $18,495 $775 $19,474 $38,744 100
Percent 48 2 50 100
DENGUE COSTS IN PUERTO RICO 749This paper is the first, to our knowledge, to use a system-
atic and comprehensive approach to estimate the economic
impact of dengue for the Commonwealth of Puerto Rico
by combining multiple sources: patient interviews, medical
records, and financial data from health facilities, insurance
companies, and patients. The methodology used assists in
addressing the variation in dengue cases observed in epidemic
versus endemic years by taking the average number of cases
reported between 2002 and 2010. To our knowledge, this
paper is also the first to show how the economic cost of a
dengue episode was distributed among different societal
groups; households, employers, insurers, and the government.
Several limitations in the study must be acknowledged.
First, the patient interviews took place, on average, 2 months
after the onset of symptoms because of the multiple steps
in analyzing the laboratory data, contacting the facility,
contacting the patient, and arranging the interview. This
unavoidable lag raised some concerns regarding recall bias.
Nevertheless, our validation showed that self-reporting of
hospital duration was reasonably accurate, with the ratios
being close to the ideal value of 1.00. Second, our sample was
limited to non-fatal cases; we used mortality data from the
Pan American Health Organization to reach our estimates
for fatal cases of 17.8% of aggregate illness cost and 14.9% of
the overall economic cost of dengue.
62 Third, because of data
limitations, we were not able to estimate the impact of dengue
on travelers or tourism. Dengue has been diagnosed in an
increasing proportion of febrile travelers returning from
infected areas, posing a risk for travelers who may both
acquire and spread dengue virus.
63–65 Research elsewhere
has shown that the potential impacts on tourism could be
substantial.
66 Therefore, our estimates are conservative.
The share of dengue costs for illness in Puerto Rico (83%)
is roughly comparable with the share from Panama (56%),
the only other known comparable study.
52 The per capita
economic cost of dengue illness, surveillance, and vector
control activities in Puerto Rico ($12.47) is double the cost
in Panama ($5.22) in 2005. Although Panama’s GDP per
capita ($4,630)
52 was much lower than the GDP for Puerto
Rico ($16,300),
40 the data from Panama come from an
epidemic year when illness costs might be unusually high.
52
The work by Suaya and others
12 estimated the economic
impact of dengue illness for officially reported dengue cases
in five countries in the Americas. This cost was $135.2 mil-
lion ($0.73 per capita) in Brazil, $10.2 million ($0.38 per
capita) in Venezuela, $1.7 million ($0.28 per capita) in
El Salvador, $1.2 million ($0.09 per capita) in Guatemala,
and $0.9 million ($0.28 per capita) in Panama.
12 The
relatively higher economic cost of dengue for officially
laboratory-confirmed dengue cases in Puerto Rico ($10.8 mil-
lion [$2.89 per capita]) is consistent with the island’s higher
GDP per capita.
The aggregate overall economic cost of dengue, including
disease surveillance and vector control, represents 0.06% of
Puerto Rico’s overall GDP for the year 2010 and based on
GDP per capita, is equivalent to the aggregate annual eco-
nomic output of 2,450 people. Because the cost of illness is
five times the cost of surveillance and vector control, it is
likely that increases in surveillance and vector control would
pay off economically. For example, if a 10% increase in
spending on vector control could reduce dengue incidence by
10%, it could reduce the cost of illness by 10% and save $5 on
illness treatment for every $1 increase in surveillance and
vector control spending. Of all publicly funded health spend-
ing in Puerto Rico, 62% is funded by the federal govern-
ment.
67 Sound investments related to dengue would benefit
not only the residents of Puerto Rico but all taxpayers
throughout the United States.
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